C-H9L9bioelectrics, biologics, regenerative medtech
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Treat or control inflammation in a subject using precise bioelectrical signaling.
Medical-device method applying bioelectric tissue signals and frequencies, potentially including brain tissue stimulation and adjunct administration, as described in patent US11110274B2.
US11110274B2 granted on 2021-09-07 and listed as active.
Support orthodontic treatment by applying electrical signals affecting teeth and bone.
Electrical-signal treatment method for orthodontics described in patent US10695563B2.
US10695563B2 granted on 2020-06-30 and listed as active.
Develop an early detection system for cancers using bioelectric neuro code signal reading.
Bioelectric signal reading based on neuro code signals.
Supplied public record states the Leonhardt team was working on bioelectric neuro code signal reading that it believes can be an early detection system for cancers.
Pipeline program associated in supplied records with cancer-treatment collaboration and bioelectric neuro-code signal reading for early cancer detection and organ regeneration follow-up.
Customized bioelectric treatment using ultra-low voltage and amperage encoded signals; also described as neuro-code signal reading.
Leonhardt Ventures announced a worldwide strategic collaboration with Neuro Code Tech Holdings for customized bioelectric cancer treatments.
Treat cancer using customized bioelectric signals intended to cause cancer cell death and potentially support organ regeneration after tumor destruction.
Ultra-low voltage and amperage encoded signals reprogrammed from cancer cell communication signals; includes application of ions to affect the glycocalyx of the outer cell membrane.
Leonhardt Ventures entered a worldwide strategic collaboration with Neuro Code Tech Holdings for customized bioelectric cancer treatments.
Deliver stem cell therapies using patented catheter technologies.
Patented stem cell delivery catheter technologies licensed to Abbott Laboratories according to supplied public record.
Bioheart sold a license to Leonhardt and other patented stem cell delivery catheter technologies to Abbott Laboratories for $900,000; Leonhardt Ventures increased its stake in Bioheart via debt conversion announced November 17, 2014.
Pipeline program apparently focused on addiction-related neuromodulation based on the public program name.
Early-stage regenerative medtech product using the company's bioelectric/regenerative platform context.
Listed in the company development pipeline; products are described as early-stage and investigational, not available for sale.
Pipeline program apparently focused on aortic regeneration or repair based on the public program name.
Early-stage regenerative medtech product using the company's bioelectric/regenerative platform context.
Listed in the company development pipeline; products are described as early-stage and investigational, not available for sale.
Regenerative medtech platform/program listed in the development pipeline.
Bioelectric signaling sequence-controlled expression of organ regeneration proteins, biologics, refillable micro-infusion pumps, and multicomponent stem-cell plus support-factor compositions.
Listed in the company development pipeline; products are described as early-stage and investigational, not available for sale.
Program listed in Leonhardt Ventures' development pipeline; supplied material does not state a more specific objective.
Early-stage regenerative medtech product using the company's bioelectric/regenerative platform context.
Listed in the company development pipeline; products are described as early-stage and investigational, not available for sale.
Pipeline program apparently focused on depression or mood-related neuromodulation based on the public program name.
Early-stage regenerative medtech product using the company's bioelectric/regenerative platform context.
Listed in the company development pipeline; products are described as early-stage and investigational, not available for sale.
Program listed in Leonhardt Ventures' development pipeline; supplied material does not state a more specific objective.
Early-stage regenerative medtech product using the company's bioelectric/regenerative platform context.
Listed in the company development pipeline; products are described as early-stage and investigational, not available for sale.
Pipeline program apparently focused on hair-related cell/regenerative treatment based on the public program name.
Early-stage regenerative medtech product using the company's bioelectric/regenerative platform context.
Listed in the company development pipeline; products are described as early-stage and investigational, not available for sale.
Pipeline program apparently related to longevity based on the public program name and company longevity/regenerative focus.
Early-stage regenerative medtech product using the company's bioelectric/regenerative platform context.
Listed in the company development pipeline; products are described as early-stage and investigational, not available for sale.
Develop early-stage regenerative medtech startups and products using bioelectric signaling, biologics, pumps, stem-cell compositions, and accelerator resources.
Bioelectric signaling sequence-controlled expression of organ regeneration proteins, refillable micro-infusion pumps, and multicomponent stem-cell plus support-factor compositions.
Products described as early-stage development and investigational use only, not available for sale.
Pipeline program apparently focused on memory-related neuromodulation based on the public program name.
Early-stage regenerative medtech product using the company's bioelectric/regenerative platform context.
Listed in the company development pipeline; products are described as early-stage and investigational, not available for sale.
Repair damaged heart tissue using muscle stem cells.
Cell therapy evaluated in a controlled Phase II study, based on the supplied publication titles.
First Phase II controlled study results reported in 2006.
Supplied publication records reference heart repair results in 2005 and first Phase II controlled study results in 2006, but no detailed outcomes are provided.
Repair damaged heart tissue using muscle stem cells.
Muscle stem cell therapy for cardiac repair; the supplied publications include non-surgical stem cell repair of hearts and Phase II controlled study results.
First Phase II controlled study results reported in supplied publication list.
Supplied publication titles indicate heart repair results and Phase II controlled study results, but no quantitative outcomes were provided.
Repair hearts without surgery using stem-cell-based intervention.
Non-surgical stem cell heart repair approach described by a supplied 2003 publication title.
First paper on non-surgical stem cell repair of hearts listed for 2003.
Pipeline program apparently focused on orthodontic or dental regeneration based on the public program name.
Early-stage regenerative medtech product using the company's bioelectric/regenerative platform context.
Listed in the company development pipeline; products are described as early-stage and investigational, not available for sale.
Regenerate the pancreas.
Total pancreas regeneration device; no further method details were included in the supplied material.
Public record title states PancreaCell unveiled a total pancreas regeneration device.
Program listed in Leonhardt Ventures' development pipeline; supplied material does not state a more specific objective.
Early-stage regenerative medtech product using the company's bioelectric/regenerative platform context.
Listed in the company development pipeline; products are described as early-stage and investigational, not available for sale.
Investigate SDF-1 as part of regenerative heart repair research.
Biologic signaling research based on the supplied publication title identifying an SDF-1 landmark paper.
SDF-1 landmark paper listed for 2003.
Investigate SDF-1 biology in regenerative heart repair.
Research program around SDF-1, inferred from supplied publication title "SDF-1 landmark paper."
Landmark SDF-1 paper listed with publication year 2003.
Program listed in Leonhardt Ventures' development pipeline; supplied material does not state a more specific objective.
Early-stage regenerative medtech product using the company's bioelectric/regenerative platform context.
Listed in the company development pipeline; products are described as early-stage and investigational, not available for sale.
Program listed in Leonhardt Ventures' development pipeline; supplied material does not state a more specific objective.
Early-stage regenerative medtech product; supplied material associates the company pipeline with bioelectric signaling, biologics, pumps, and stem-cell compositions.
Listed in the company development pipeline; products are described as early-stage and investigational, not available for sale.
Pipeline program apparently focused on skin-related bioelectric stimulation based on the public program name.
Early-stage regenerative medtech product using the company's bioelectric/regenerative platform context.
Listed in the company development pipeline; products are described as early-stage and investigational, not available for sale.
Pipeline program apparently focused on spine-related bioelectric stimulation based on the public program name.
Early-stage regenerative medtech product using the company's bioelectric/regenerative platform context.
Listed in the company development pipeline; products are described as early-stage and investigational, not available for sale.
Repair thoracic Type B dissections and aortic aneurysms.
Endovascular stent graft device.
Publication listed for thoracic Type B dissection repair of aortic aneurysms with TALENT stent graft in 1999.
Repair thoracic Type B dissection aortic aneurysms using a stent graft.
Taheri-Leonhardt TALENT stent graft described in a supplied 1999 publication title.
Publication listed in 1999 on thoracic Type B dissection repair of aortic aneurysms with TALENT stent graft.
Pipeline program apparently focused on tremor-related bioelectric stimulation based on the public program name.
Early-stage regenerative medtech product using the company's bioelectric/regenerative platform context.
Listed in the company development pipeline; products are described as early-stage and investigational, not available for sale.
Program listed in Leonhardt Ventures' development pipeline; supplied material does not state a more specific objective.
Early-stage regenerative medtech product using the company's bioelectric/regenerative platform context.
Listed in the company development pipeline; products are described as early-stage and investigational, not available for sale.
Program listed in Leonhardt Ventures' development pipeline; supplied material does not state a more specific objective.
Early-stage regenerative medtech product using the company's bioelectric/regenerative platform context.
Listed in the company development pipeline; products are described as early-stage and investigational, not available for sale.
Program listed in Leonhardt Ventures' development pipeline; supplied material does not state a more specific objective.
Early-stage regenerative medtech product using the company's bioelectric/regenerative platform context.
Listed in the company development pipeline; products are described as early-stage and investigational, not available for sale.